¼¼°èÀÇ Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP) ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Çâ, ¾÷°è ºÐ¼®(À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°), ¿¹Ãø(2025-2034³â)
Platelet Rich Plasma (PRP) Market Size, Share, Trends, & Industry Analysis Report By Type (Pure, Leukocyte, Pure Platelet-Rich Fibrin), By Application, By End Use, By Region - Market Forecast, 2025-2034
»óǰÄÚµå : 1762471
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 113 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 5,973,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,378,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,784,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ¼¼°è Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP) ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 28¾ï 5,798¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP)Àº Àç»ýÀÇ·á ¹× Ä¡·á ºÐ¾ßÀÇ ÁÖ¿ä ¼ººÐÀ¸·Î Á¶Á÷ º¹±¸ ¹× Ä¡À¯¿¡ ´ëÇÑ Á¢±Ù ¹æ½ÄÀ» Å©°Ô º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ȯÀÚ ÀÚ½ÅÀÇ Ç÷¾×¿¡¼­ ÃßÃâÇÑ PRP´Â ¾Ë·¹¸£±â ¹ÝÀÀ À§Çè °¨¼Ò, ȸº¹ ½Ã°£ ´ÜÃà µî ±âÁ¸ Ä¡·á¹ý¿¡ ºñÇØ ¸î °¡Áö ÀåÁ¡ÀÌ ÀÖÀ¸¸ç, PRPÀÇ ¾ÈÀü¼º, È¿´É, ÀÚ¿¬ Ä¡À¯·Â¿¡ ÈûÀÔ¾î ¼ºÇü¿Ü°ú, ÇǺΰú, ½ºÆ÷Ã÷ ÀÇÇÐ, ¸ÞµðÄà ¿¡½ºÅׯ½ ºÐ¾ß¿¡¼­ PRP¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¡Á¡ ´õ ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.

PRP ½ÃÀåÀº Áö¼ÓÀûÀÎ °úÇÐÀû ¹ßÀü°ú ½ÇÁ¦ ÀÓ»ó ÇöÀå ¼ö¿ä Áõ°¡·Î ÀÎÇØ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ¼¼°è °¢±¹ Á¤ºÎ´Â ÀÚ±Ý, ¿¬±¸ º¸Á¶±Ý, À¯¸®ÇÑ ±ÔÁ¦¸¦ ÅëÇØ Àç»ý ÀǷḦ Áö¿øÇϰí ÀÖÀ¸¸ç, PRP ±â¹Ý Ä¡·á¹ýÀÇ °³¹ß ¹× äÅÃÀ» Àå·ÁÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ¿äÀεéÀº Á¶Á÷ º¹±¸ ¹× ±Ù°ñ°Ý°è Ä¡À¯¿Í °°Àº ºÐ¾ß¿¡¼­ PRP Ä¡·áÀÇ »ç¿ëÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °ñ°üÀý¿°, ÈûÁÙ ¼Õ»ó, Å»¸ð¿Í °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â Àα¸ °í·ÉÈ­ ¹× »ýȰ½À°ü º¯È­¿Í °ü·ÃÀÌ ÀÖÀ¸¸ç, ÀÌ´Â PRP¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í ºÎÃß±â°í ÀÖÀ¸¸ç, PRP´Â Á¶Á÷ Àç»ý ¹× Ä¡À¯¸¦ ÃËÁøÇϱ⠶§¹®¿¡ ÀÓ»ó ¹× ¹Ì¿ë ¿ëµµ ¸ðµÎ¿¡¼­ ±ÍÁßÇÑ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù.

¹Ì±¹ ¼ºÇü¿Ü°ú Àü¹®ÀÇ¿Í ÇǺΰú Àü¹®ÀǵéÀÌ ÇǺÎÀÇ º¼·ý, »öÁ¶, Áú°¨À» °³¼±Çϱâ À§ÇØ PRP Ä¡·áÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖÀ¸¸ç, ¹Ì±¹ ¼ºÇü¿Ü°úÇÐȸ´Â 2023³â ¹Ì±¹¿¡¼­¸¸ ¾à 590¸¸ °ÇÀÇ Àç°Ç ¼ö¼úÀÌ ÃÖ¼Òħ½ÀÀû ¼ö¼úÀÇ ¼±µÎÁÖÀÚ·Î º¸°íÇϰí ÀÖ½À´Ï´Ù.

Ç÷¼ÒÆÇdzºÎÇ÷Àå ½ÃÀå : ºÐ¼® °³¿ä

À¯Çüº°·Î´Â ¼ø¼ö Ç÷¼ÒÆÇdzºÎÇ÷Àå(P-PRP) ¶Ç´Â Èñ¼Ò¹éÇ÷±¸ ¹× Ç÷¼ÒÆÇdzºÎÇ÷Àå ºÎ¹®ÀÌ 2024³â Ç÷¼ÒÆÇdzºÎÇ÷Àå ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â À§Çè°ú ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϰí Ä¡·á Áß ¾Ë·¹¸£±â ¹× ¸é¿ª ¹ÝÀÀ°ú °ü·ÃµÈ ¿ì·Á¸¦ ÁÙÀÏ ¼ö ÀÖ´Ù´Â ºÐ¸íÇÑ ÀÌÁ¡ÀÌ Àֱ⠶§¹®ÀÔ´Ï´Ù.

¿ëµµº°·Î´Â ÇǺΰú ºÐ¾ß°¡ 2024³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ±Þ¼ºÀåÀÇ ¹è°æ¿¡´Â ÇǺΠȸÃá, ¿©µå¸§ ÈäÅÍ Ä¡·á, ¸ð¹ß Àç»ý µî ºñ¼ö¼úÀû ¹Ì¿ë ¼ºÇü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ÁÖ¿ä ¿øÀÎÀ¸·Î ºÐ¼®µË´Ï´Ù. ¹Ì¿ë Ä¡·á¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÇǺΠÁú°¨ ¹× ¸ð¹ß ¼ºÀåÀ» °³¼±Çϱâ À§ÇÑ PRPÀÇ ÀαⰡ ³ô¾ÆÁø °ÍÀÌ ÀÌ·¯ÇÑ ¼ºÀå¿¡ Å©°Ô ±â¿©Çß½À´Ï´Ù. ÇǺΰú ÀÇ»çµéÀº ´Ù¾çÇÑ ÇǺΠÁúȯÀ» Ä¡·áÇϱâ À§ÇØ PRP¸¦ »ç¿ëÇÏ¿© Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â 2024³â ¼¼°è Ç÷¼ÒÆÇdzºÎÇ÷Àå ½ÃÀåÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀº ¹Ì¿ë ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¼ºÇü ¼ö¼úÀÇ ³ôÀº º¸±Þ·ü, ½ºÆ÷Ã÷ °ü·Ã ºÎ»ó ¹ß»ý·ü Áõ°¡ÀÔ´Ï´Ù. ¶ÇÇÑ, ¸¶ÀÌÅ©·Î´ÏµéÀº ÇǺΠȸÃáÀ̶ó´Â º»·¡ÀÇ ¿ëµµ ¿Ü¿¡µµ °æÇÇÀû ¾à¹° Åõ¿© µî ´Ù¾çÇÑ ¿ëµµ·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

À¯·´ Ç÷¼ÒÆÇdzºÎÇ÷Àå ½ÃÀåÀº ±Ù°ñ°Ý°è ¼Õ»ó Ä¡·á¿¡ PRP ¿ä¹ýÀÌ ±¤¹üÀ§ÇÏ°Ô Ã¤ÅõǸ鼭 Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¾ÆÅ³·¹½º°Ç¿°, Á·Àú±Ù¸·¿°, Å״Ͻº ¿¤º¸ µîÀÇ ÁúȯÀÌ ÀÌ·¯ÇÑ Áõ°¡ Ãß¼¼¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¼¼°è ÁÖ¿ä ±â¾÷À¸·Î´Â Vivostat;&Arthrex Inc.;&RegenOrthoSport;&Dr. PRP USA LLC;&Juventix Regenerative Medical, LLC;&Terumo Cardiovascular Systems Corporation;&Zimmer Biomet;&Isto Biologics;&Apex Biologix;& Regen Lab SA. µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ºÐ¼® ¹æ¹ý

Á¦4Àå ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå Ç÷¼ÒÆÇdzºÎÇ÷Àå ½ÃÀå Æò°¡ : À¯Çüº°

Á¦6Àå Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP) ½ÃÀå Æò°¡ : ¿ëµµº°

Á¦7Àå Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP) ½ÃÀå Æò°¡ : ÃÖÁ¾ ¿ëµµº°

Á¦8Àå Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP) ½ÃÀå Æò°¡ : Áö¿ªº°

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global platelet rich plasma (PRP) market size is expected to reach USD 2,857.98 million by 2034, according to a new study by Polaris Market Research. The report "Platelet Rich Plasma (PRP) Market Size, Share, Trends, & Industry Analysis Report By Type (Pure, Leukocyte, Pure Platelet-Rich Fibrin), By Application, By End Use, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Platelet rich plasma (PRP) is a key component in the field of regenerative medicine and therapeutic treatments, significantly transforming approaches in tissue repair and healing. Derived from a patient's own blood, PRP offers several advantages over conventional treatment methods, such as reduced risk of allergic reactions and faster recovery times. The growing demand for PRP is fueled by its safety, effectiveness, and natural healing properties, making it an increasingly preferred option across orthopedics, dermatology, sports medicine, and medical aesthetic procedures.

The PRP market is expanding rapidly due to ongoing scientific advancements and increasing demand in real world clinical settings. Government worldwide is supporting regenerative medicine through funding, research grants, and favorable regulations which is encouraging the development and adoption of PRP based treatments. Therefore, these factors have accelerated the usage of PRP therapies in areas such as tissue repair and musculoskeletal healing. Additionally, the growing prevalence of chronic conditions such as osteoarthritis, tendon injuries, and hair loss, which are often linked to aging populations and lifestyle changes, is further fueling demand for PRP. PRP further promotes tissue regeneration and healing, making it a valuable tool in both clinical and cosmetic applications.

The growing adoption of PRP treatments by plastic surgeons and dermatologists to enhance skin volume, tone, and texture has contributed significantly to the growth of the market. As the top minimally invasive procedure of 2023, the American Society of Plastic Surgeons reported nearly 5.9 million reconstructive procedures in the US alone.

Platelet Rich Plasma Market Report Highlights

Based on type, the pure platelet-rich plasma (P-PRP) or leukocyte-poor platelet-rich plasma segment dominated the platelet rich plasma market share in 2024, due to its distinct advantage with minimal risk and adverse effects, reducing concerns related to allergies and immune responses during treatments.

By application, the dermatology segment accounted for the largest share in 2024. The rapid growth is attributed to the growing demand for nonsurgical cosmetic surgery, such as skin rejuvenation, acne scar treatment, and hair restoration. Increased awareness of aesthetic treatments and the rising popularity of PRP for improving skin texture and hair growth significantly contributed to this growth. Dermatologists are using PRP to address diverse skin conditions, expanding treatment options.

North America dominated the global platelet rich plasma market revenue share in 2024. This market is primarily driven by increasing demand for cosmetic surgeries, a high prevalence of orthopedic procedures, and a rising incidence of sports-related injuries. Furthermore, micro-needling is gaining popularity for various applications, including transcutaneous drug administration, in addition to its original intended use for skin rejuvenation.

The platelet rich plasma market in Europe is experiencing significant growth, owing to the widespread adoption of PRP therapy for the treatment of musculoskeletal injuries. Conditions such as Achilles tendinopathy, plantar fasciitis, and tennis elbow are particularly contributing to this upward trend.

A few global key market players are Vivostat; Arthrex Inc.; RegenOrthoSport; Dr. PRP USA LLC; Juventix Regenerative Medical, LLC; Terumo Cardiovascular Systems Corporation; Zimmer Biomet; Isto Biologics; Apex Biologix; and Regen Lab SA.

Polaris Market Research has segmented the platelet rich plasma market report on the basis of type, application, end use, and region:

By Type Outlook (Revenue, USD Million, 2020-2034)

Pure Platelet-Rich Plasma (P-PRP)

Leukocyte-and Platelet-Rich Plasma (L-PRP)

Pure Platelet-Rich Fibrin (P-PRF) - or Leukocyte-Poor Platelet-Rich Fibrin

Leukocyte- and Platelet-Rich Fibrin (L-PRF)

By Application Outlook (Revenue, USD Million, 2020-2034)

Orthopedics

Sports Medicine

General Surgery

Dermatology

Ophthalmology

Neurology

Cardiology

Others

By End Use Outlook (Revenue, USD Million, 2020-2034)

Hospitals

Clinics

Others

By Regional Outlook (Revenue, USD Million, 2020-2034)

North America

US

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Malaysia

Australia

Indonesia

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

Rest of Middle East & Africa

Latin America

Brazil

Argentina

Rest of Latin America

Table of Contents

Chapter 1. Introduction

Chapter 2. Research Methodology

Chapter 3. Executive Summary

Chapter 4. Market Insights

Chapter 5. Platelet Rich Plasma (PRP) Market Assessment by Type

Chapter 6. Platelet Rich Plasma (PRP) Market Assessment by Application

Chapter 7. Platelet Rich Plasma (PRP) Market Assessment by End-Use

Chapter 8. Platelet Rich Plasma (PRP) Market Assessment by Region

Chapter 9. Competitive Landscape

Chapter 10. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â